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Abstract
Background: Small molecules tackling mutated BRAF (BRAFi) are an important main‐
stay of targeted therapy in a variety of cancers including melanoma. Albeit commonly 
reported as side effect, the phototoxic potential of many BRAFi is poorly character‐
ized. In this study, we evaluated the phototoxicity of 17 distinct agents and investi‐
gated whether BRAFi‐induced phototoxicity can be alleviated by antioxidants.
Methods: The ultraviolet (UV) light absorbance of 17 BRAFi was determined. Their 
phototoxic potential was investigated independently with a reactive oxygen species 
(ROS) and the 3T3 neutral red uptake (NRU) assay in vitro. To test for a possible 
phototoxicity alleviation by antioxidants, vitamin C, vitamin E phosphate, trolox, and 
glutathione (GSH) were added to the 3T3 assay of selected inhibitors.
Results: The highest cumulative absorbance for both UVA and UVB was detected 
for vemurafenib. The formation of ROS was more pronounced for all compounds 
after irradiation with UVA than with UVB. In the 3T3 NRU assay, 8 agents were clas‐
sified as phototoxic, including vemurafenib, dabrafenib, and encorafenib. There was 
a significant correlation between the formation of singlet oxygen (P = .026) and su‐
peroxide anion (P < .001) and the phototoxicity observed in the 3T3 NRU assay. The 
phototoxicity of vemurafenib was fully rescued in the 3T3 NRU assay after GSH was 
added at different concentrations.
Conclusion: Our study confirms that most of the BRAF inhibitors exhibited a con‐
siderable phototoxic potential, predominantly after exposure to UVA. GSH may help 
treat and prevent the phototoxicity induced by vemurafenib.
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1  | INTRODUC TION
The identification of somatic mutations of the BRAF gene has paved 
the way for targeted therapy with small molecules in a variety of 
cancer entities in recent years.1 Activating genetic alterations of co‐
dons encoding for the kinase domain of BRAF results in constitutive 
oncogenic signaling through the Ras‐Raf‐MEK‐ERK mitogen‐acti‐
vated protein kinase (MAPK) pathway, leading to cell proliferation 
and, ultimately, tumor growth.2 Mutations of BRAF have been found 
in more than 66% of human cancers and are suspected to be present 
in an even wider range of malignancies at a lower frequency.3
Encouraged by these observations, major pharmaceutical efforts 
have been made at high pace to develop small molecules targeting 
mutant BRAF. As the target protein with and without the mutation 
of interest could be structurally elucidated in its active and inactive 
conformation via crystallography, a hitherto never utilized drug de‐
sign strategy was employed, namely fragment‐based lead discovery. 
Here, smaller well‐binding structures are joined covalently to form 
a superiorly target‐binding drug candidate.4 As a result, the BRAF 
inhibitors (BRAFi) vemurafenib and dabrafenib were developed and 
approved by the FDA for the treatment of metastatic or unresect‐
able melanoma in 2011 and 2013, respectively, showing substantial 
survival benefits compared with chemotherapy.5,6 In 2018, a third 
inhibitor, encorafenib, has been approved in combination with the 
MEK inhibitor binimetinib.7 All substances selectively bind to and 
inhibit the active‐state BRAF kinase, with most BRAFi sharing com‐
mon structural motifs: the A ring binding in the nucleobase‐binding 
pocket, the B ring as a sterically important stiff core, the BC linker 
(salt bridge linker) for ionic interactions, and the lipophilic C ring.8 
As the A ring resembles the aromatic, bicyclic adenine‐moiety of 
the native substrate ATP, most inhibitors rely on a mono‐ or bicyclic, 
heavily substituted aromatic structure for strong binding charac‐
teristics. For this reason, most inhibitors exhibit strong UVA absor‐
bance which is a prerequisite for UVA‐induced phototoxicity. This 
cutaneous adverse event is well known for vemurafenib, while the 
phototoxic potential of dabrafenib and encorafenib is much lower in 
pivotal trials.9‐13 However, the phototoxic potential of other BRAFi 
is poorly characterized and has not been analyzed in a systematic 
approach yet. Therefore, in this study we comparatively evaluated 
the phototoxicity of 17 distinct BRAFi or multikinase inhibitors and 
tested whether phototoxicity can be reduced by antioxidants in 
vitro.
2  | MATERIAL S AND METHODS
2.1 | Chemicals
All BRAF inhibitors, including AZ628, CEP‐32496, dabrafenib, en‐
corafenib, GDC‐0879, GW5074, LY3009120, MLN2480, NVP‐
BHG712, PLX‐4720, RAF265, RO5126766, SB590885, sorafenib 
tosylate, TAK‐632, vemurafenib, and ZM336372 were purchased 
from Selleck Chemicals LLC. Concentrations of the inhibitor stock 
solutions in DMSO were normalized to the least soluble compound 
(sorafenib tosylate) at 7.85 mM. Control compounds (chlorproma‐
zine, quinine, and sulisobenzone), antioxidants such as ascorbic 
acid (vitamin C), (±)‐α‐tocopherol phosphate disodium salt (vitamin 
E phosphate), (±)‐6‐hydroxy‐2,5,7,8‐tetramethylchromane‐2‐car‐
boxylic acid (trolox, vitamin E analog), and glutathione (GSH), and 
additional chemicals were purchased from Sigma‐Aldrich. Stock so‐
lutions were stored frozen and protected from light. Ultraviolet‐visi‐
ble spectra of the test compounds were determined with an IMPLEN 
NanoPhotometer™.
2.2 | Irradiation conditions
Irradiance is defined as the intensity of UV or visible light incident 
on a surface, measured in W/m2 or mW/cm2. Cells in 96‐well plates 
were illuminated with either UVA light by F8T5/PUVA fluorescent 
tubes (main emission 320‐410 nm, maximum 351 nm) or UVB light 
by broadband TL 20W/12 RS ultraviolet‐B fluorescent tubes (main 
emission 290‐320 nm, maximum 302 nm). The irradiation tests were 
performed at 25°C with an irradiance of approximately 4.1 mW/
cm2 (UVA) or 0.41 mW/cm2 (UVB) which was tested prior to each 
experiment.
2.3 | Cell culture methods
Sterile cell culture plasticware was obtained from Greiner BioOne 
and Sarstedt, while chemicals and media were acquired from 
Gibco/Invitrogen and Sigma‐Aldrich. Mouse BALB/c embryo 3T3 
clone A31 fibroblasts were purchased from the European collec‐
tion of cell cultures (ECACC) via Sigma‐Aldrich. The cells were 
used between passage numbers 30‐40. All illumination proce‐
dures were performed in a photobiology laboratory with no meas‐
urable UV light levels (Waldmann). 3T3 cells were maintained in 
DMEM (Dulbecco's Modified Eagle Medium, 4.5 g/L glucose) sup‐
plemented with 10% fetal bovine serum (FBS), 4 mmol/L stable 
glutamine, penicillin (100 IU), and streptomycin (100 µg/mL), and 
humidified incubation at 37°C with 5% CO2. Cells were subcul‐
tured every 3‐4 days.
2.4 | Reactive oxygen species assay
The reactive oxygen species (ROS) assay was developed to test for 
the generation of a reactive species from chemicals following ab‐
sorption of UV‐visible light, as a key determinant of chemicals for 
causing phototoxic reactions.14 Based on the OECD/OCDE guide‐
lines for the ROS assay tests, stock solutions of all chemicals were 
prepared at 20 mmol/L in sodium phosphate buffer (NaPB, pH 7.4) 
or at 7.85 mmol/L in DMSO. About 0.2 mmol/L p‐nitrosodimethy‐
laniline (RNO) was prepared by dissolving 3 mg of RNO in 100 mL 
of 20 mmol/L NaPB. About 13.6 mg of imidazole was dissolved 
in 10 mL of 20 mmol/L NaPB, and the 2 × 10−2 mol/L imidazole 
solution was diluted 100 times with 20 mmol/L NaPB, forming 
a 20 mmol/L imidazole compound. About 0.4 mmol/L nitroblue 
tetrazolium chloride (NBT) was prepared by dissolving 32.7 mg of 
128  |     HEPPT ET al.
NBT in 100 mL of 20 mmol/L NaPB. Quinine hydrochloride (QUI) 
and sulisobenzone (SIB) were used as positive and negative con‐
trols, respectively.15
The test procedure for this assay included a 1.5 mL micro tube 
and a plastic clear flat bottomed 96‐well microplate. The reaction 
mixtures were prepared by vortex mixing under UV‐cut illumina‐
tion. For each reaction mixture, triplicates of 200 µL per well were 
transferred into a 96‐well plate and solubility and coloration were 
checked microscopically at 100‐fold magnification. After shaking 
the plate for 5 seconds, baseline absorbance at 440 nm (A440) for 
SO and 560 nm (A560) for SA was measured prior to UV exposure. 
The plate was irradiated with a UVA simulator for 1 hour, and A440 
and A560 were measured again. Based on the assay protocol, SO was 
determined as a result of bleaching of p‐nitrosodimethylaniline by 
oxidized imidazole. The measurement of SA was made upon the re‐
duction of nitroblue tetrazolium16:
2.5 | In vitro 3T3 NRU phototoxicity test
Identification by this test increases the likelihood of substances 
to be phototoxic in vivo after systemic or topical application.17 
Phototoxicity of the BRAFi was determined according to the OECD/
OCDE 432 guideline with minor modifications.18 For the experi‐
ments, 3T3 cells were seeded into 96‐well plates at a density of 
5 × 104 cells per well. The outer wells of each plate were left empty. 
All test compounds were checked for degradation by determination 
of the UV‐visible spectra (IMPLEN NanoPhotometer™) prior to each 
experiment. After 24 hours, the cells were washed with phosphate‐
buffered saline (PBS) and incubated with the inhibitors at different 
concentrations (100 µmol/L, 10 µmol/L, 1 µmol/L, 100 nmol/L, 
10 nmol/L, 0 nmol/L or 100 µmol/L, 31.6 µmol/L, 10 µmol/L, 
3.16 µmol/L, 1 µmol/L, and 0 µmol/L) in Earle's balanced salt solu‐
tion (EBSS) with low bicarbonate (0.085%) for 1 hour in the dark at 
37°C. Chlorpromazine (CPZ) and quinine (QUI) were used as positive 
controls, sulisobenzone (SIB) as negative control for UV phototoxic‐
ity. The percentage of solvents in the experiments did not exceed 
1.2% (v/v) at the highest concentrations tested.
After incubation of two identical 96‐well plates, one was exposed 
to either UVA (total dose: 5 J/cm2) or UVB (total dose: 20 mJ/cm2) 
light and the other one was covered in lightproof aluminum foil and 
incubated under the UV lamp as well. Subsequently, the cells were 
washed with PBS and incubated in DMEM supplemented with FBS 
at 37°C overnight. On the following day, cells were washed with PBS 
and incubated in DMEM without FBS containing 50 µg/mL neutral 
red (NR) dye at 37°C for 2 hours. Cells were washed with PBS and 
blotted to remove buffer remains. Precisely, 150 µL desorb solution 
(50% ethanol v/v, 1% acetic acid (v/v)) was added per well and the 
plate was incubated at room temperature for 10 minutes with gentle 
shaking. The absorbance of the resulting homogeneously pink solu‐
tion was measured without a lid at 540 nm in a plate reader (Spectra 
MR, Dynex Technologies). The outer wells of each plate were used 
as reference.
2.6 | Phototoxicity alleviation through antioxidants
To test for an effect on the BRAFi‐mediated toxicity, antioxidants 
were added to the 3T3 NRU phototoxicity test of selected inhibi‐
tors. The concentrations of the tested antioxidants were 100, 10, 
and 1 µmol/L for vitamin C, vitamin E phosphate, and trolox, and 
10 mmol/L, 1 mmol/L, and 100 µmol/L for GSH. The concentrations 
of the BRAFi vemurafenib, dabrafenib, and encorafenib were 3.16, 1, 
and 10 µmol/L, respectively.
2.7 | Data evaluation
Each data point was at least measured in duplicate and in two inde‐
pendent experiments. To visualize the data, dose‐response curves 
were created, showing relative viability against the BRAFi concen‐
tration applied at a fixed irradiation dose (no UV, UVA, UVB). The 
IC50 was defined as the concentration reducing cell viability to 50% 
compared with that of untreated control cultures. IC50 values were 
calculated via curve fits using GraphPad Prism® 5 for Windows. 
Phototoxicity was calculated according to the OECD 432 guideline, 
where the “photo‐irritation‐factor” (PIF; ratio of IC50noUV to IC50UV) 
was used to estimate the risk.18 Based on the validation study, a PIF 
value less than 2 predicts no phototoxicity, a value between 2 and 
5 probable phototoxicity, and more than 5 phototoxicity.17 In some 
cases, not both IC50 could be determined, so that the published ad 
hoc rules were applied (prediction model 1): First, if only one IC50 
can be measured, the other value is replaced by the highest con‐
centration tested; the chemical is considered phototoxic if the ratio 
is greater than 1. Second, if no IC50 can be measured, the chemical 
is considered non‐phototoxic.19 The correlation between the for‐
mation of SO or SA in the ROS assay and phototoxicity observed 
in the 3T3 NRU assay was calculated with Pearson's correlation. 
Differences of phototoxicity after the addition of antioxidants were 
compared with the student's t test. A two‐sided P‐value was cal‐
culated in all cases and values of P < .05 considered as statistically 
significant.
3  | RESULTS
3.1 | UV spectral analysis of BRAF kinase inhibitors
Initially, the UV absorbance spectrum of the 17 Raf inhibitors 
was determined. All inhibitors showed a certain amount of UVA 
(λUVA = 315 to 410 nm) and UVB light (λUVB = 280 to 315 nm) ab‐
sorbance (Figure 1A). The substance with the highest absorption 
of UVA light was GW5074. The area under the curve (AUC) of this 
compound was set to 1 for UVA (Figure 1C). It was closely followed 
SOgeneration=1000× [A440 (noUVA)−A440 (UVA)− (solvent(noUVA)−solvent(UVA))]
SAgeneration=1000× [A560 (noUVA)−A560 (UVA)− (solvent(UVA)−solvent(UVA))]
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by SB590885 (relative absorption 0.8). Out of the 4 inhibitors ap‐
proved for cancer treatment, vemurafenib and dabrafenib ap‐
peared to have the highest rates of UVA light absorptions (relative 
absorptions 0.3), with encorafenib following at a slightly lower 
rate (relative absorption 0.2). The only RAF kinase inhibitor exhib‐
iting almost no UVA light absorption was sorafenib tosylate (rela‐
tive absorption 0) (Figure 1B).
The highest absorbance of UVB was observed for NVP‐BHG712 
whose AUC and relative absorption was set to 1 (Figure 1C). 
Compared with its absorbance of UVA, sorafenib tosylate displayed 
a much higher absorption of UVB (relative absorption 0.5) in our 
spectral analysis. Interestingly, the highest amount of UVB absorp‐
tion amongst the approved BRAFi was recorded again for vemu‐
rafenib (relative absorption 0.8) and the lowest for encorafenib 
(relative absorption 0.2) (Figure 1B). The absorbance curve for ve‐
murafenib showed a peak at the border between UVB and UVA and 
then decreased after 340 nm (Figure 1A and B).
3.2 | In chemico generation of reactive oxygen 
species upon exposure to UVA and UVB light
In chemico SO and SA generation induced by BRAFi upon exposure 
to UVA and UVB was analyzed. Dabrafenib was the only chemical 
showing increased SA levels after UV irradiation while also leading 
to increased SO formation. Only 3 out of 17 compounds generated 
SO species following absorption of UVB light, whereas, after ab‐
sorption of UVA light, 9 chemicals including encorafenib resulted in 
increased levels of SO. Interestingly, vemurafenib and sorafenib to‐
sylate belonged to the 7 substances where no phototoxic response 
was detected (Table 1).
3.3 | In vitro 3T3 NRU phototoxicity assay
We compared the IC50 values acquired in the light and dark experi‐
ments by calculating the PIF. Since most BRAFi showed no toxicity 
F I G U R E  1   In chemico analysis of UV absorption spectrum of Raf inhibitors. A, absorbance of UVA (λUVA = 315‐410 nm) and UVB 
light (λUVB = 280‐315 nm) of 17 Raf inhibitors was determined. B, UV absorbance of the approved inhibitors vemurafenib, dabrafenib, 
encorafenib, and sorafenib tosylate. C, Relative UV absorbance of the 17 tested compounds determined by the area under the curve (AUC). 
The AUC of GW5074 and NVP‐BHG712 was set to 1 for UVA and UVB, respectively. All other AUCs were normalized to these values 
[Colour figure can be viewed at wileyonlinelibrary.com]
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without irradiation in the concentrations tested, the ad hoc rules 
were applied. Six of the 17 chemicals under evaluation were clas‐
sified according to the PIF values as non‐phototoxic (GDC‐0879, 
RAF265, RO5126766, SB590885, sorafenib tosylate, ZM336372) 
(Figure 2C), 3 as probably phototoxic (CEP‐32496, LY3009120, 
PLX‐4720) (Figure 2B), and 8 as phototoxic (AZ628, dabrafenib, 
encorafenib, GW5074, MLN2480, NVP‐BHG712, TAK‐632, vemu‐
rafenib) (Figure 2A). The highest PIFUVA values were calculated for 
dabrafenib (≥925.1), followed by TAK‐632 (≥61.9), and encorafenib 
(≥55.7). No substantial UVB phototoxicity could be recorded as all 
PIFUVB values were close to 1, although no threshold values have 
been reported in the literature (Table 2).
3.4 | Phototoxicity alleviation through antioxidants
Comparing the results of the ROS and the 3T3 NRU phototoxicity 
assay, we detected a significant correlation between the phototoxic‐
ity observed in the 3T3 NRU assay and the formation of both SO 
(Pearson r = .5365; P = .026) and SA (Pearson r = .9139; P < .001) in 
the ROS assay. To test for an inhibitory effect on the BRAFi‐medi‐
ated toxicity, antioxidants were added to the 3T3 NRU phototox‐
icity test of selected inhibitors. The phototoxicity of the approved 
BRAFi vemurafenib, dabrafenib, and encorafenib was analyzed in 
the presence or absence of UVA light for different concentrations 
of glutathione (GSH), trolox, vitamin C, and vitamin E. Of all tested 
antioxidants, high‐dose GSH was able to fully rescue the phototoxic‐
ity observed with vemurafenib after exposure to UVA (Figure 3A). In 
contrast, the phototoxicity induced by dabrafenib and encorafenib 
was left unaltered after antioxidants were added at different con‐
centrations (Figure 3B and 3C).
4  | DISCUSSION
Activating mutations of BRAF can be found in 40%‐60% of patients 
suffering from advanced melanoma, leading to consistent activation 
of downstream signaling through the MAPK pathway.3 This discov‐
ery has provided an important target for small‐molecule drugs that 
have successfully been introduced in the recent years for melanoma 
therapy. However, patients treated with BRAFi frequently develop 
cutaneous adverse reactions, such as cutaneous squamous cell car‐
cinoma, verrucal keratosis, and photosensitivity, which can severely 
impact the quality of life.20 Even though phototoxicity belongs to 
the most commonly reported adverse events since the introduction 
of the first BRAFi vemurafenib, the phototoxic potential of other 
inhibitors has not been systematically analyzed yet.5,21 Therefore, 
we tested the phototoxicity of 17 different BRAFi and investigated 
whether phototoxicity can be rescued by adding antioxidants in 
vitro.
The generation of reactive oxygen species following UV light ir‐
radiation can lead to oxidative damage to the cell. UVA light plays 
a more significant role in causing phototoxicity than other UV 
ranges.22,23 This is consistent with the results of the ROS assay that 
was performed in this study with UVA and UVB light. Only 3 out of 
Inhibitor
ROS assay
+UVB +UVA
Singlet oxygen Superoxide anion Singlet oxygen Superoxide anion
AZ628 + − − −
CEP‐32496 − − − −
Dabrafenib + + + +
Encorafenib − − + −
GDC‐0879 − − + −
GW5074 − − + −
LY3009120 − − − −
MLN2480 + − + −
NVP‐BHG712 − − + −
PLX‐4720 − − − −
RAF265 − − + −
RO5126766 − − − −
SB590885 − − + −
Sorafenib 
tosylate
− − − −
TAK‐632 − − + −
Vemurafenib − − − −
ZM336372 − − − −
Abbreviations: −, ROS not detectable; +, ROS detectable.
TA B L E  1   Analysis of in chemico ROS 
generation upon exposure to UVA and 
UVB light according to the cut‐off values 
of the OECD guideline for the testing of 
chemicals.15
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F I G U R E  2   In vitro 3T3 NRU phototoxicity assay. 3T3 mouse fibroblasts were exposed to different concentrations of inhibitors and 
irradiated with UVA or UVB light. A photo irritation factor (PIF: ratio of IC50noUV to IC50UV) was calculated to estimate the phototoxic 
potential of each test compound. Dose‐response curves of A, phototoxic (PIF > 5), B, probably phototoxic (PIF ranging from 2 to 5), and C, 
not phototoxic test substances (PIF < 2) are shown [Colour figure can be viewed at wileyonlinelibrary.com]
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Phototoxic
PIF > 5
Probably phototoxic
PIF 2 to 5
Not phototoxic
PIF < 2
AZ628 >10.004 CEP‐32496 >2.91 GDC‐0879 >1.08
Dabrafenib >925.069 LY3009120 >3.867 RAF265 0
Encorafenib >55.679 PLX‐4720 >3.667 RO5126766 0
GW5074 >7.127   SB590885 0
MLN2480 >8.834   Sorafenib tosylate >1.021
NVP‐BHG712 >11.089   ZM336372 0
TAK‐632 >61.92     
Vemurafenib >5.634     
TA B L E  2   Photo irritation factors (PIF; 
ratio of IC50noUV to IC50UV) of the 17 
tested Raf inhibitors upon exposure to 
UVA light
F I G U R E  3   Efficacy of antioxidants as inhibitors of phototoxicity in vitro. The inhibiting effects of the antioxidants glutathione (GSH), 
trolox, vitamin C, and vitamin E on the drug‐induced phototoxicity of the BRAF kinase inhibitors vemurafenib (A), dabrafenib (B), and 
encorafenib (C) were analyzed; *P < .05, **P < .01, and ***P < .001 vs control (+ UVA, Ø antioxidant)
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17 substances induced the formation of ROS following irradiation 
with UVB light compared with 9 agents which generated ROS after 
UVA light absorption. Surprisingly, vemurafenib elicited no ROS re‐
lease in our assay, although its UVA‐dependent phototoxicity is well 
established in daily care and in the literature.9,24 These results imply 
that the phototoxicity observed with vemurafenib clinically is not 
mediated by ROS. In contrast, we observed that dabrafenib, which in 
the clinical practice is considered much less phototoxic than vemu‐
rafenib, was the only substance leading to the formation of both SO 
and SA after UVA and UVB exposure. Thus, our results fit well with a 
recent study, in which vemurafenib but not dabrafenib impaired the 
repair of UV‐induced DNA damage in keratinocytes.25 These results 
suggest that the phototoxicity experienced by patients under BRAFi 
in vivo may not primarily be mediated by ROS formation and imply 
that also other mechanisms are likely to be involved. Above that, we 
conclude that the ROS assay may not accurately predict the photo‐
toxicity which is clinically relevant and observed in vivo.
Another test which has proved to be predictive of acute photo‐
toxicity effects in animals and humans in vivo is the 3T3 NRU photo‐
toxicity test.18 Overall, 8 compounds including the BRAFi approved 
for melanoma encorafenib, vemurafenib, and dabrafenib were iden‐
tified as phototoxic by this test. In accordance with the ROS assay 
results, the 3T3 NRU test results also confirmed the phototoxicity 
of dabrafenib with a considerable PIF value over 900, the highest 
among all test chemicals. Vemurafenib, in contrast to the ROS assay 
results, proved to be phototoxic in the 3T3 NRU test, whereas its PIF 
value (>5.634) was much lower than that of dabrafenib. Nevertheless, 
the results observed in our 3T3 NRU assays were in line with various 
in vivo studies, which have shown emergence of photosensitivity 
during vemurafenib or dabrafenib therapy.6,24 The reason why the 
phototoxicity in vivo of dabrafenib is lower than suggested by the 
ROS and the 3T3 NRU assay remains unclear. Our data support a hy‐
pothesis by Gabeff et al that dabrafenib is a phototoxic agent per se 
but has a different triggering cut‐off for a reaction to UVA radiation 
compared with vemurafenib. Another explanation for the difference 
between the high phototoxicity detected in vitro and low frequence 
of phototoxic adverse events experienced in vivo is the slight delay 
of dabrafenib studies compared with those of vemurafenib, during 
which patients had already received the advice for sun‐protection.22 
Furthermore, the cumulative UV absorbance did not correlate well 
with the phototoxicity observed in the 3T3 assay for all substances. 
In particular, agents with high absorbance for UVB such as RAF265, 
RO5126766, and SB590885 were classified as non‐phototoxic in the 
3T3 assay. In contrast, other agents with high UVB absorbance such 
as NVP‐BHG712 and vemurafenib were classified as phototoxic 
in this assay, underlining that the amount and type of absorbance 
did not necessarily reflect their phototoxic potential. Of the 6 test 
chemicals without phototoxic potential (PIF < 2) in the 3T3 NRU 
assay, only the multikinase inhibitor sorafenib is used in the clinical 
routine. Our results are consistent with the assessments of other 
studies that have reported numerous sorafenib‐associated dermato‐
logic side effects which, however, rarely include phototoxicity.26,27
To alleviate the BRAFi‐induced phototoxicity, we tested a panel 
of antioxidants as an attempt to find feasible alternatives for the 
management of phototoxicity.28,29 Accordingly, the physiological 
antioxidants vitamin C, vitamin E, trolox, and GSH were added to 
the 3T3 NRU phototoxicity assay with the BRAFi vemurafenib, dab‐
rafenib, and encorafenib. Interestingly, we observed that high‐dose 
GSH was able to fully rescue the UVA‐induced phototoxicity of 
vemurafenib. GSH is a tripeptide best known for its role as antiox‐
idant by neutralizing ROS. However, as no induction of ROS was ob‐
served with vemurafenib, it is likely that other functions of GSH are 
involved. It has general cytoprotective properties and can stabilize 
cellular components after DNA damage.30 Thus, our data support a 
model where UV‐induced damage repair is impaired by vemurafenib 
and that this process can be alleviated by GSH, independently from 
the generation of ROS. Although our understanding of the protec‐
tive effects of GSH on the vemurafenib‐induced phototoxicity is 
certainly limited, substances that increase GSH may represent an in‐
teresting option to protect patients from phototoxicity also in vivo. 
Further studies are warranted to fully explore the potential of GSH 
in both the treatment and prevention of phototoxic reactions due to 
vemurafenib.
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